### **At-a-Glance**

### **COVID-19 Vaccination Schedule for Most People**





(People who are NOT Moderately or Severely Immunocompromised)






# People ages 5 through 11 years






### People ages 12 years and older



#### People ages 18 years and older who previously received Janssen primary series dose<sup>†</sup>



#### For more specific clinical guidance, see:

- Pre-exposure prophylaxis
- Interim COVID-19 Immunization Schedule
- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States

Note: This schedule does not include clinical details necessary for administering COVID-19 vaccines. For clinical details, see the resources at the end of this document.


- \* The bivalent booster dose is administered at least 2 months after completion of the primary series. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.
- † Janssen COVID-19 Vaccine should only be used in certain limited situations. See: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a

### **At-a-Glance**


## **COVID-19 Vaccination Schedule for People Who Are Moderately or Severely Immunocompromised**



#### People ages 6 months through 4 years



#### People ages 5 years through 11 years



#### For more specific clinical guidance, see:

- Pre-exposure prophylaxis
- Interim COVID-19 Immunization Schedule
- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States

#### **At-a-Glance**


### **COVID-19 Vaccination Schedule for People Who Are Moderately or Severely Immunocompromised**



#### People ages 12 years and older




People ages 18 years and older who previously received Janssen primary series dose<sup>†</sup>



# Monoclonal antibodies (EVUSHELD™) for COVID-19 pre-exposure prophylaxis

People ages 12 years and older (must weigh at least 40kg)



#### For more specific clinical guidance, see:

- Pre-exposure prophylaxis
- Interim COVID-19 Immunization Schedule
- Interim Clinical
   Considerations for
   Use of COVID-19
   Vaccines Currently
   Approved or
   Authorized in the
   United States

Note: This schedule does not include clinical details necessary for administering COVID-19 vaccines. For clinical details, see the resources at the end of this document.

- \* The bivalent booster dose is administered at least 2 months after completion of the primary series. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.
- † Janssen COVID-19 Vaccine should only be used in certain limited situations. See: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a